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Objectives: Tuberculosis remains one of the top three infectious disease killers.
The prevalence of multidrug-resistant tuberculosis (MDR-TB) has increased sub-
stantially in the past 20 years. When drug resistance is not detected, MDR-TB
patients cannot access life-saving treatment; this puts their communities at risk
of ongoing MDR-TB transmission. We aimed to determine the patterns of resis-
tance to antituberculosis drugs among Mycobacterium tuberculosis isolates from
Khuzestan province in Iran.
Methods: A total of 850 clinical specimens from patients suspected of active TB
were cultured in 2015. Drug susceptibility testing to the first line antiTB drugs for
culture positive MTB was performed on LowensteineJensen medium using the
proportion method.
Results: Of 850 cultured specimens, 272 (32%) were culture positive for myco-
bacteria. Of 64 MTB isolates that were analyzed by the proportion method, 62
(96.8%) were pan-susceptible and two (3.1%) were MDR.
Conclusion: An important way to prevent the emergence of MDR and XDR TB, and
the principles of full implementation of the strategy is directly observed treat-
ment, short-course (DOTS). The efficient diagnosis and timely treatment of MDR-
TB patients can prevent disease transmission, reduce the risk of drug resistance
developing, and avoid further lung damage.1. Introduction
Tuberculosis is a leading cause of death by an in-
fectious disease worldwide, despite global efforts and
financial investment by governments andBadie).
ase Control and Prevention.
reativecommons.org/licensnongovernmental organizations in disease-control pro-
grams during the past 20 years [1].
The World Health Organization (WHO) estimates
that onethird of the world’s population is infected with
Mycobacterium tuberculosis, resulting in an estimated 8Published by Elsevier Korea LLC. This is an open access article
es/by-nc-nd/4.0/).
Drug Resistance Pattern of Mycobacterium tuberculosis 33million new cases of tuberculosis and nearly 2 million
deaths each year [2].
Antituberculosis (TB) drug resistance is a major
public health problem that threatens progress made in
TB care and control worldwide [3]. Drug resistance
arises due to improper use of antibiotics in chemo-
therapy of drug-susceptible TB patients and because of
insufficient diagnostic facilities. This improper use is a
result of a number of actions including, administration
of improper treatment regimens and failure to ensure
that patients complete the whole course of treatment
[4,5]. A patient who develops active disease with a drug-
resistant TB strain can transmit this form of TB to other
individuals. Drug-resistant bacteria specially multidrug-
resistant tuberculosis (MDR) and extensively drug-
resistant (XDR), persists as a global public health
problem [6].
In 2011, WHO estimated 12 million prevalent cases
of tuberculosis worldwide, of which w630,000 (w5%)
were multidrug resistance(MDR) tuberculosis. MDR-TB
is caused by TB organisms that are resistant to the first-
line drugs, isoniazid and rifampin, used to treat in-
dividuals with TB [7].
According to WHO, the estimated incidence rate of
tuberculosis in Iran is 21 per 100,000 of the popula-
tion. Therefore, control and prevention of TB in Iran
is the main health concern of the national TB program
[7].
Early diagnosis of TB is important for prevention of
its spread and one way of reducing MDR-TB. The gold
standard test for diagnosis of TB is through the culture
method [8].
Culture remains the most sensitive method for the
detection of M. tuberculosis in clinical specimens.
Isolation in culture provides for all subsequent testing,
including identification and antibiotic susceptibility
testing. Culture is capable of detecting as few as
101e102 organisms/mL of specimen, surpassing the
sensitivity of smear (104 CFU/mL) [9,10].
Accurate drug susceptibility testing (DST) for M.
tuberculosis is highly important for both therapy guid-
ance and surveillance of drug resistance. DST should be
performed for individuals at high risk of drug resistance
including patients with treatment failure and chronic TB
cases (most high risk), Individuals with close contact
with diagnosed MDR-TB patients, patients with treat-
ment failure in the first treatment group, patients whose
sputum smear at the end of the acute phase of treatment
becomes or still remains positive, patients with pulmo-
nary TB/HIV and in prisons [11].
The present study was designed to determine drug
resistance pattern of MTB isolates from patients referred
to the TB reference laboratory in Ahwaz (south western
part of Iran, bordering with Iraq) during a 6-month
period.2. Materials and methods
2.1. Study population and samples
The study was approved by the Ethics Committee of
the Ahwaz Jundishapor University of Medical Science
in Ahwaz, Iran.
The study was conducted in 2015.The studied pop-
ulation composed of 850 clinical individuals who were
referred to the TB reference laboratory in Ahwaz. A
total of 513 samples belonged to men, 334 samples
belonged to women, and 45 samples were taken from
prisoners (Table 1).
2.2. Identification of mycobacteria
Smear and culture of specimen for acid fast bacilli
was performed on all patients.
Samples from each patient were decontaminated by
Petroff’s method and were inoculated into Low-
ensteineJensen media. The bacterial suspension (1 mL)
was decontaminated with sodium hydroxide (NaOH) at
a final concentration of 0.5N for 20 minutes at room
temperature with intermittent agitation and then
neutralized with 1N hydrochloric acid (HCl). This sus-
pension was then centrifuged at 2,500g for 20 minutes to
pellet the bacilli and then resuspended in sterile saline at
a concentration of 107 bacilli/mL [12].
2.3. Inoculation and incubation
Glass or plastic pasture pipettes were used and each
slope was inoculated with 0.2e0.4 mL (2e4 drops) of
the centrifuged sediment. Cultures were incubated in a
slanted position for at least 24 hours to ensure the
complete distribution of inoculum. All cultures were
incubated at 35e37C until growth was observed or
discarded as negative after 2 months.
Biochemical and phenotypic methods for identifica-
tion of mycobacteria include observation of rate of
growth, colony morphology, pigmentation, and
biochemical profiles. Biochemical testing (i.e., niacin,
nitrate reduction, and 68C labile catalase tests) was
used to identify the isolated mycobacteria once they
were categorized into a preliminary subgroup based on
their growth characteristics [13].
2.4. Drug susceptibility testing
Drug susceptibility testing for cases that were ordered
by doctor were performed, for example HIV positive
patients, prisoners, and patients with relapse.
The susceptibilities of the isolates which were iden-
tified as M. tuberculosis were determined against
isoniazid, rifampicin, ethambutol, and streptomycin by
standard proportional method using LowensteineJensen
medium as recommended by WHO. This method is
considered to be a reference standard against which
other routine methods should be assessed.
Table 1. The age distribution of cases.
Age (y) %
18e50 42.3
> 50 50.7
< 18 7
Table 3. Pattern of drug resistance by treatment exposure
groups.
Drug resistance pattern n (%)
Pun susceptible 62 (96.8)
Multidrug resistant 2 (3.1)
Mono-drug resistant 0
34 F. Badie, et alSusceptibility was defined as no or < 1% growth on
media containing the critical concentration of drug
(0.2 mg/mL for isoniazid (INH), 2.0 mg/mL for etham-
butol (EMB), 4 mg/mL for streptomycin (STM), and
40 mg/mL for rifampicin (RMP). Resistance was defined
as growth in the number of colonies of > 1% in the drug
containing media as compared with the nondrug-
containing media [14].3. Results
Of 850 clinical specimens received by the TB refer-
ence laboratory in Ahwaz, 35% was smear positive
(Table 2). All of the 850specimen were cultured and 272
specimens of them were M. tuberculosis (32%).3.1. Drug susceptibility patterns
Drug susceptibility testing was performed for 64
patients according to physician orders (Table 3). A total
of 60 isolates were from male patients and four from
female patients, 62 specimens (96.8%) were pan-
susceptible, and two specimens (3.1%) were resistant
to isoniazid and rifampin (MDR-TB).
Both isolates of drug-resistant M. tuberculosis,
belonged to women.
Sensitivity was defined as follows: isoniazid 0.2 mg/
mL, rifampin 40 mg/mL, ethambutol 2 mg/mL, and
streptomycin 4 mg/mL.
The drug susceptibility pattern was interpreted ac-
cording to WHO guidelines [15].4. Discussion
Drug susceptibility testing for TB is the most effective
tool of control and management of MDR-TB. The effi-
cient diagnosis and timely treatment of MDR-TB patientsTable 2. Smear test results by positivity grade.
Smear positivity score %
<1þ 9
1þ 15
2þ 12
3þ 64can prevent disease transmission, reduce the risk of drug
resistance developing, and avoid further lung damage.
In this study, the resistance of M. tuberculosis to
isoniazid and rifampin (MDR TB) was 3.1%. In a 2006
survey in Khuzestan, the rate of MDR-TB was reported
as 8.7% by conventional Minimal Inhibitory Concen-
tration (MIC) method and 6.2% by Polymerase Chain
Reaction (PCR) technique [16]. A study from the Na-
tional Research Institute of Tuberculosis and Lung
Disease in Iran, that presented drug resistance patterns
of TB from 2003 to 2008, has shown that 2% of MTB
isolates from new cases were MDR [17].
The prevalence of MDR-TB in Iran, in the year 2011,
was 5% for new cases as reported by WHO [18]. A
study by Alavi and Salami [19] showed that mortality
rates of tuberculosis in Khuzestan was 3.15%, (2.8% in
females and 3.3% in males).
The incidence of smear positive pulmonary TB in
Khuzestan, south west Iran, is estimated to be 25 per
100,000 of the population [20]. In a study by Nasiri et al
[21], drug resistance of M. tuberculosis isolates from
patients of five provinces of Iran was determined and
6.3% MDR were seen. Another study by Metanat et al
[22] in Zahedan showed that 16% of patients were
MDR. In study by Hadizadeh Tasbiti et al [23], between
2006 and 2009, the rate of MDR TB was 2.5%.
The basic and most important way to prevent the
emergence of MDR and XDR-TB, and the principles of
full implementation of the strategy is directly observed
treatment, short-course (DOTS).Conflicts of interest
All authors have no conflicts of interest to declare.
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